37941-69-8

Usage

Uses

Used in Pharmaceutical Industry:
4-Hydroxy-N-methylbutyramide is used as an intermediate in the synthesis of hypotensive agents for the treatment of high blood pressure. Its chemical structure allows for the development of drugs that can effectively manage blood pressure levels, providing a valuable contribution to the pharmaceutical industry's efforts in combating hypertension.
As an intermediate, 4-Hydroxy-N-methylbutyramide plays a crucial role in the production of hypotensive medications, which are essential for maintaining cardiovascular health and preventing related complications such as stroke, heart attack, and kidney disease. Its application in this field highlights the importance of organic chemistry in the development of life-saving medications.

InChI:InChI=1/C5H11NO2/c1-6-5(8)3-2-4-7/h7H,2-4H2,1H3,(H,6,8)

Upstream product

• 96-48-0 4-butanolide 
• 74-89-5 methylamine 
• 28341-54-0 4-(4-nitrophenoxy)butanoic acid 
• 1121-07-9 N-methylsuccinimide 
• 18190-25-5 N,N-dimethyl-γ-hydroxybutyramide 
• 124-40-3 dimethyl amine 

Downstream Products

• 340026-90-6 5'-O-(4,4'-dimethoxytrityl)-3'-O-(N,N-diethylamino)[3-(N-methylaminocarbonyl)-1-propyloxy]phosphinyl-2'-deoxythymidine 
• 120-94-5 1-Methylpyrrolidine 
• 872-50-4 1-methyl-pyrrolidin-2-one 
• 1121-07-9 N-methylsuccinimide 
• 382600-67-1 5'-thymidyl benzyl N-methyl-N-(4-chlorobutyl) phosphoramidate 

Relevant academic research and scientific papers

RAPAMYCIN ANALOGS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY

A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.

A Study on the Intramolecular Mitsunobu Reaction of N6-(ω-Hydroxyalkyl)adenines

The cyclization of N6-(ω-hydroxyalkyl)adenines with a N6H-group leads to N6,N1 ring closure regardless of the method of the cyclization that was used. Five-membered to eight-membered rings were obtained using NBS/PPh3; however, under Mitsunobu conditions, the eight-membered fused purine was not formed. Surprisingly, the cyclization of N6-methyl-N6-(4-hydroxybutyl)adenine only leads to N6,N7 ring closure using both methods.

VALSARTAN DERIVATIVES CARRYING NITROGEN OXIDE DONORS FOR THE TREATMENT OF VASCULAR AND METABOLIC DISEASES

Nitrate esters and diazeniumdiolate derivatives of valsartanamide are described. They have valuable properties in the treatment of vascular and metabolic diseases.

A valsartanamide dinitrate derivative for the treatment of vascular and metabolic diseases

A dinitrate ester of a valsartanamide is described. It has superior properties in the treatment of vascular and metabolic diseases.

A mild and facile synthesis of cyclic imides using pyridinium chlorochromate

A mild and facile synthetic method of cyclic imides is presented. These compounds are widely used in the synthesis of novel medical, polymeric, photonic and electronic materials. Compared with traditional syntheses, the method reported has several advantages including mild conditions, simplified work-up and low cost.

Desymmetrization of meso-cyclic imides via enantioselective monohydrogenation

meso-Cyclic imides are monohydrogenated to form the corresponding hydroxy lactams in 88-97% ee using trans-[Ru((R)-BINAP)(H)2((R,R)-dpen)] and related compounds as catalysts with base in THF. The hydrogenation proceeds with high enantiogroup-and chemoselectivity, and it is a desymmetrization reaction, forming up to five stereogenic centers in one reaction. Conversion of a hydroxy lactam into the corresponding iminium ion followed by addition of indene extended the number of stereogenic centers from 5 to 7.

PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II

Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formula I, II, III, I′, II′, I″, II″, Ia, IIa, or IIIa, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

PROCESS FOR THE PREPARATION OF N-AKYL-PYRROLIDONES

A process for the production of N-alkylpyrrolidone from γ-butyrolactone and monoalkylamine in the liquid phase comprising the steps of: feeding monoalkylamine and γ-butyrolactone, in the absence of water or in the presence of less than about 1 wt % of water, to a reaction zone to form a reaction mixture; heating the reaction mixture; withdrawing a product stream from the reaction zone and passing the stream to a distillation zone comprising at least one distillation column operated at sub-atmospheric pressure; adding water to the distillation zone; isolating at least one overhead stream from the distillation zone comprising monoalkylamine, water and optionally N-alkyl-pyrrolidone and condensing the overhead stream against cooling water.

Methods of making intermediates from polyhydroxyalkanoates

Methods of forming intermediates from PHAs are disclosed.